Chosa Oncology

Company profile

Chosa Oncology company profile

Chosa Oncology is a biotechnology company with a focus on the late-stage clinical development of innovative cancer treatments. With a team of 10 employees, the company specializes in creating solutions aimed at preventing cancer recurrence and progression following primary tumor therapy. Chosa Oncology's flagship technology, iCIP, represents a novel approach in the use of cisplatin, enhancing safety and efficacy for patients who benefit from this treatment. The company also developed the Drug Response Predictor (DRP®), an in vitro diagnostic tool that utilizes a multigene mRNA-based analysis to predict patient response to its cisplatin drug. Chosa Oncology holds strong patent protection for its technologies until 2038, underscoring its commitment to advancing cancer treatment through innovation.